Treatment nonadherence: Causes and potential solutions

Journal of the American Psychiatric Nurses Association

Volumn 8, Issue 4 SUPPL., 2002, Pages

  Jarboe, Kathleen S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DECANOIC ACID DERIVATIVE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EXPECTATION; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HEALTH PRACTITIONER; HOSPITALIZATION; HUMAN; INJECTION PAIN; MENTAL DISEASE; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PSYCHOSIS; PUNISHMENT; RELAPSE; RISK ASSESSMENT; THREAT;

EID: 0036674104     PISSN: 10783903     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpn.2002.127060     Document Type: Article

References (31)

1. Compliance and the rehabilitation alliance
2. Medication compliance: A healthcare problem
3. Schizophrenics fully remitted on neuroleptics for 3-5 years-to stop or continue drugs?
4. Compliance with medication regimens for mental and physical disorders
5. Depot antipsychotic drugs: Place in therapy
6. Do schizophrenics well adapted in the community need neuroleptics?
7. Understanding and improving patient compliance
8. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
9. Compliance with chronic disease regimens: Diabetes
10. One-year outcome of schizophrenic patients: The interaction of chronicity of neuroleptic treatment
11. Depot neuroleptics in relapse prevention: Advantages and disadvantages
12. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients
13. Depot neuroleptic therapy: An underutilized treatment option
14. Introduction
15. Compliance with depot antipsychotic medication by patients attending outpatient clinics
16. Drug discontinuation among long term, successfully maintained schizophrenic outpatients
17. Long-term maintenance treatment in chronic schizophrenia: Some observations on outcome and duration
18. The duration of maintenance therapy in chronic schizophrenia
19. Efficacy and safety of Risperdal Consta™ a long-acting injection rispetidone formulation
20. Positive and Negative Syndrome Scale (PANSS)
21. The struggle over medications: A look at the factors affecting the use of psychoactive drugs
22. A comparison of rehospitalization rates between patients treated with atypical antipsychotics and those treated with depot antipsychotics
23. Klinikaufenthalte und produktive ruckfalle bei ersterkrankten schizophrenen
24. Common sense, insight, and neuropsychological test performance in schizophrenia patients
25. The rehabilitation alliance
26. Medication noncompliance and substance abuse among patients with schizophrenia
27. Adherence to antipsychotic medications
28. Compliance in children and adults: A review of studies
29. Rating of medication influences (ROMI) scale in schizophrenia
30. Cost of relapse in schizophrenia
31. A depot neuroleptic withdrawal study: A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients